Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Orfao

Showing results (301-310 of 504) with videos related to

Pageof 51
Sort By:
Frontiers in Immunology|March 20, 2019
The EuroFlow PID Orientation Tube for Flow Cytometric Diagnostic Screening of Primary Immunodeficiencies of the Lymphoid SystemMirjam van der Burg, Tomas Kalina, Martin Perez-Andres, et al.
Frontiers in Immunology|July 23, 2024
A novel NKp80-based strategy for universal identification of normal, reactive and tumor/clonal natural killer-cells in bloodF Javier Morán-Plata, Noemí Muñoz-García, María González-González, et al.
Archives of Pathology & Laboratory Medicine|October 7, 2021
Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple MyelomaAlejandro Medina, Cristina Jiménez, Noemí Puig, et al.
Cancers|October 13, 2021
Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in MyelomaNoemí Puig, Juan Flores-Montero, Leire Burgos, et al.
British Journal of Haematology|September 22, 2021
Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocolsJordi Ribera, Isabel Granada, Mireia Morgades, et al.
Leukemia Research|January 30, 2007
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conferencePeter Valent, Hans-Peter Horny, John M Bennett, et al.
Oncotarget|July 3, 2018
Prognostic stratification of adult primary glioblastoma multiforme patients based on their tumor gene amplification profilesMaría González-Tablas, Inês Crespo, Ana Luísa Vital, et al.
Hemasphere|December 31, 2025
Impact of the kinetics of circulating anti-BCMA CAR-T cells and normal lymphocytes on the outcome of MM patientsSara Gutiérrez-Herrero, Lourdes Martín-Martín, María Herrero-García, et al.
Blood|February 15, 2003
Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical valueMaría-Belén Vidriales, José J Pérez, Maria Consuelo López-Berges, et al.
Journal of Immunological Methods|October 3, 2017
Selection and validation of antibody clones against IgG and IgA subclasses in switched memory B-cells and plasma cellsElena Blanco, Martin Perez-Andres, Luzalba Sanoja-Flores, et al.
Pageof 51

Showing results (301-310 of 504) with videos related to

Sort By:
Pageof 51
Frontiers in Immunology|March 20, 2019
The EuroFlow PID Orientation Tube for Flow Cytometric Diagnostic Screening of Primary Immunodeficiencies of the Lymphoid SystemMirjam van der Burg, Tomas Kalina, Martin Perez-Andres, et al.
Frontiers in Immunology|July 23, 2024
A novel NKp80-based strategy for universal identification of normal, reactive and tumor/clonal natural killer-cells in bloodF Javier Morán-Plata, Noemí Muñoz-García, María González-González, et al.
Archives of Pathology & Laboratory Medicine|October 7, 2021
Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple MyelomaAlejandro Medina, Cristina Jiménez, Noemí Puig, et al.
Cancers|October 13, 2021
Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in MyelomaNoemí Puig, Juan Flores-Montero, Leire Burgos, et al.
British Journal of Haematology|September 22, 2021
Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocolsJordi Ribera, Isabel Granada, Mireia Morgades, et al.
Leukemia Research|January 30, 2007
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conferencePeter Valent, Hans-Peter Horny, John M Bennett, et al.
Oncotarget|July 3, 2018
Prognostic stratification of adult primary glioblastoma multiforme patients based on their tumor gene amplification profilesMaría González-Tablas, Inês Crespo, Ana Luísa Vital, et al.
Hemasphere|December 31, 2025
Impact of the kinetics of circulating anti-BCMA CAR-T cells and normal lymphocytes on the outcome of MM patientsSara Gutiérrez-Herrero, Lourdes Martín-Martín, María Herrero-García, et al.
Blood|February 15, 2003
Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical valueMaría-Belén Vidriales, José J Pérez, Maria Consuelo López-Berges, et al.
Journal of Immunological Methods|October 3, 2017
Selection and validation of antibody clones against IgG and IgA subclasses in switched memory B-cells and plasma cellsElena Blanco, Martin Perez-Andres, Luzalba Sanoja-Flores, et al.
Pageof 51